Key terms
About SMMT
Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SMMT news
Apr 11
4:52pm ET
Summit Therapeutics Appoints Biotech Veteran to Board
Apr 03
4:52pm ET
Summit Therapeutics Announces Major Leadership Restructuring
Mar 27
8:44pm ET
Summit Therapeutics CFO buy $375K in common stock
Mar 27
8:44pm ET
Summit Therapeutics CEO buys $411K in common stock
Mar 25
4:25pm ET
Summit Therapeutics’ Ivonescimab: A Potential New Standard in Oncology Market Challenging Keytruda
Mar 25
4:14pm ET
Summit Therapeutics initiated with a Buy at Stifel
Mar 22
7:13am ET
Summit presents ivonescimab data at 2024 European Lung Cancer Congress
Mar 12
8:52am ET
Summit Therapeutics Showcases at Barclays Healthcare Conference
Feb 27
4:35am ET
SHAREHOLDER ALERT: Potential Recovery for Summit Therapeutics Inc. (SMMT) Investors
Feb 23
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Feb 22
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 20
7:57am ET
Summit Therapeutics files to sell 2.98M shares of common stock for holders
Feb 20
7:57am ET
Summit Therapeutics files $450M mixed securities shelf
Feb 15
5:43pm ET
Summit Therapeutics Highlights Innovations at Healthcare Conference
Feb 09
4:38am ET
Summit Therapeutics Presents at Annual Healthcare Conference
Jan 19
11:24am ET
Biotech Alert: Searches spiking for these stocks today
No recent press releases are available for SMMT
SMMT Financials
Key terms
Ad Feedback
SMMT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SMMT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range